Form 4: Crinetics Director Sells 5,000 Shares Under 10b5-1 Plan

Crinetics Pharmaceuticals Director Rogerio Vivaldi Coelho sold 5,000 shares of common stock for approximately $180,740 through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Rogerio Vivaldi Coelho, a Director of Crinetics Pharmaceuticals, Inc. (CRNX), sold a total of 5,000 shares of common stock.
• The sales occurred on March 12, 2026, through open market transactions.
• The transactions were executed automatically under a Rule 10b5-1 trading plan adopted on December 11, 2025.
• One block of 4,477 shares was sold at a volume-weighted average price of $36.08 per share, with a price range of $35.65 to $36.53.
• Another block of 523 shares was sold at a volume-weighted average price of $36.77 per share, with a price range of $36.69 to $36.89.
• Following these transactions, the reporting person beneficially owns 16,300 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling can sometimes be a negative signal, the execution under a pre-arranged 10b5-1 plan mitigates concerns that it's based on new, adverse information.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than a reaction to recent negative company news.

Negatives

• A director selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces insider ownership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, is a common occurrence in the biotechnology and pharmaceutical sectors, where executives often manage personal portfolios and liquidity needs. While not inherently negative, significant or widespread insider selling across multiple executives could signal concerns about future prospects, though this single transaction by one director under a pre-planned schedule is less indicative of such broader issues.

Related Party Transactions

• The sale of common stock by Rogerio Vivaldi Coelho, a Director of Crinetics Pharmaceuticals, Inc., constitutes a related party transaction as it involves an insider of the company.

Stakeholder Impact

• Shareholders: May view the director's sale as a slight negative due to reduced insider ownership, though the 10b5-1 plan context lessens immediate concern.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Key Dates

Recommendation

The transaction is a routine insider sale executed under a pre-arranged 10b5-1 plan, which typically does not reflect new material information about the company's prospects. It's a neutral event that doesn't warrant a change in investment thesis based solely on this filing. Investors should continue to hold based on the company's fundamentals and broader market conditions.

Keywords

Crinetics Pharmaceuticals, CRNX, Form 4, Insider Sale, Director Transaction, Rule 10b5-1, Stock Sale, Equity Transaction